AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).

Mark A. Socinski,Alexander I. Spira,Luis Paz-Ares,Martin Reck,Shun Lu,Makoto Nishio,Jiang Li,Yunfei Zhou,Joon Rhee,Sandra Chica Duque,Xinmin Yu

AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).

2021

Mark A. Socinski
Alexander I. Spira
Luis Paz-Ares
Martin Reck
Shun Lu
Makoto Nishio
Jiang Li
Yunfei Zhou
Joon Rhee
Sandra Chica Duque
Xinmin Yu

TPS9128Background: Monotherapy with programmed death 1 (PD-1)/PD-L1 antibodies has improved clinical outcomes for patients (pts) with non-oncogenic driven NSCLC but clinical responses are limited b...

Keywords:

PD-L1
locally advanced
Cancer research
TIGIT
Antibody
Monoclonal antibody
Medicine
non-small cell lung cancer (NSCLC)
Pembrolizumab
Ligand (biochemistry)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations